SCHEMBL24711778

SCHEMBL24711778

Cc1ccc(-c2nc3cc(C(C)C)ccc3o2)cc1NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.68
▸ TP53 P04637 6/20 0.68
▸ THRB P10828 3/20 0.64
▸ LMNA P02545 2/20 0.64
▸ POLB P06746 1/20 0.60
▸ HDAC3 O15379 1/20 0.58
▸ HDAC1 Q13547 1/20 0.58
▸ HDAC2 Q92769 1/20 0.58
▸ HDAC8 Q9BY41 1/20 0.58
▸ HDAC6 Q9UBN7 1/20 0.58
▸ USP2 O75604 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ MAOA P21397 1/20 0.56
▸ ADRA1A P35348 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24711203 0.90 MAPT (0.70) MAPTTP53THRBLMNAPOLB
SCHEMBL24711202 0.89 MAPT (0.66) MAPTTP53THRBLMNAHDAC6
SCHEMBL24711515 0.83 TP53 (0.80) MAPTTP53LMNAUSP2HSD17B10
SCHEMBL24710992 0.81 MAPT (1.00) MAPTTP53THRBPOLBHSD17B10
SCHEMBL24710830 0.80 MAPT (0.71) MAPTTP53THRBLMNAUSP2
SCHEMBL27188314 0.80 MAPT (0.78) MAPTTP53THRBLMNAPOLB
SCHEMBL2739309 0.79 MAPT (0.76) MAPTTP53LMNAPOLBHDAC3
SCHEMBL24710856 0.78 THRB (0.70) MAPTTP53THRBLMNAUSP2
SCHEMBL24710982 0.77 TP53 (0.75) MAPTTP53THRBLMNAPOLB
SCHEMBL24711185 0.76 MAPT (0.60) MAPTTP53LMNAPOLBHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF NEURALEXO, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF IRF3, IRF2BP2, STAT1 MAPT 4038/4885TP53 673/4885THRB 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback